By Fineline Cube 
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB 8.352 billion (USD 1.22 billion) in revenue, representing 1.39% year-over-year (YOY) growth, while net profit declined 9.88% YOY to RMB 2.427 billion (USD 350 million).
Financial Performance Summary
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Total Revenue | RMB 8.352B (USD 1.22B) | +1.39% |
| Net Profit | RMB 2.427B (USD 350M) | -9.88% |
| R&D Investment | RMB 889M (USD 130M) | 10.64% of revenue |
| International Revenue | RMB 4.449B (USD 650M) | +15.70% |
| Domestic Revenue | RMB 3.903B (USD 570M) | -11.13% |
Geographic Revenue Analysis
International Business (53% of Total Revenue)
- Overall Growth: +15.70% YOY to RMB 4.449 billion
- Developing Markets: +15% YOY growth
- European Market: Over 25% YOY growth, continuing high-growth trajectory
- Strategic Impact: International segment now represents majority of total company revenue
Domestic Business (47% of Total Revenue)
- Overall Performance: -11.13% YOY decline to RMB 3.903 billion
- Primary Challenges: Widespread operational pressures on medical institutions and tightened procurement budgets
- Market Context: Medical device industry remains in weak recovery cycle post-pandemic
- Bright Spots:
- IVD Business: Steadily gained market share; now accounts for 50% of domestic revenue
- Emerging Business: Strong growth momentum with +18% YOY increase, representing 23% of domestic revenue
Product Line Performance
| Product Line | Revenue (Q1 2026) | YOY Change | % of Total Revenue |
|---|---|---|---|
| In Vitro Diagnostics (IVD) | RMB 3.193B (USD 460M) | +4.96% | 38% |
| Life Information & Support | RMB 2.264B (USD 330M) | -5.86% | 27% |
| Medical Imaging | RMB 1.396B (USD 200M) | -11.83% | 17% |
| Emerging Business | RMB 1.398B (USD 200M) | +18.22% | 17% |
Emerging Business Highlights
- Minimally Invasive Surgery: High-value consumables including ultrasonic scalpels and endoscopic staplers began scaling up
- Minimally Invasive Intervention: 25% YOY growth driven by procedure volume recovery and product adoption
- Growth Trajectory: Emerging business now contributes nearly one-fifth of total company revenue
Strategic Investment & Innovation
- R&D Commitment: Maintained strong investment at 10.64% of operating revenue
- Customer Focus: Continued emphasis on achieving breakthroughs with key high-volume customers
- Market Positioning: Leveraging international strength to offset domestic headwinds
- Product Portfolio: Diversification strategy showing success in high-growth segments
Market Context & Outlook
The results reflect the bifurcated recovery pattern in China’s medical device sector, where international markets demonstrate robust demand while domestic institutions face ongoing budget constraints. Mindray’s strategic pivot toward higher-margin emerging businesses and international expansion appears to be mitigating domestic weakness, though near-term profitability pressure persists.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, market conditions, and strategic initiatives. Actual results may differ due to risks including domestic healthcare spending patterns, international market dynamics, and competitive pressures.-Fineline Info & Tech